Breaking News! Domestic Brain-Computer Interface Product Successfully Implanted, Paralyzed Patient Able to Stand Post-Surgery
Release time:
2024-11-15
China's brain-computer interface research has welcomed a significant breakthrough! China's first brain-computer interface product, NEO, completed a successful implantation surgery at Fudan University-affiliated Huashan Hospital. This marks the first clinical application of this technology in Shanghai, bringing unprecedented hope to paralyzed patients.
A week ago, Xiao Dong, who had been paralyzed for four years, anticipated a new beginning at the neurosurgery operating table of Fudan University-affiliated Huashan Hospital. The surgical procedure involved thinning the skull and implanting the coin-sized brain-computer interface, NEO (Neural Electronic Opportunity). A cranial window was created, two electrodes were placed outside the dura mater, and then the cranial window was closed. The minimally invasive surgery was completed in less than half a day. Within three days, Xiao Dong was able to get out of bed and sit in a wheelchair. This Friday, Xiao Dong was discharged from the hospital.
This marks the third brain-computer interface clinical trial implant surgery in the country and the first in Shanghai. The NEO brain-computer interface product used in the surgery was collaboratively developed by Burui Kang Medical Technology (Shanghai) Co., Ltd. and Professor Hong Bo's team from the Department of Biomedical Engineering at Tsinghua University. It became the first brain-computer interface product to enter China's special review procedure for innovative medical devices in August. This surgery was the first human implantation since the product entered the special review procedure.
Unlike the brain-computer interface products from Elon Musk's Neuralink, "the implanted brain-computer interface system employs a semi-invasive design, and it is very small, only the size of a coin, implanted above the skull and beneath the scalp. After the surgery, medical staff cover the patient's scalp, and once the hair grows back, the device is almost unnoticeable," stated the research team.
Currently, the team is developing higher-density, higher-throughput electrodes to cover a broader range of brainwave areas. In the future, they plan to shift R&D goals towards the lower spine to explore how to help patients stand up.
Latest developments
The debut and discourse of the YinFeng Life Continuation Project not only served as an authoritative demonstration of its own ethical governance framework but also contributed practical wisdom toward establishing industry norms.
Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross
Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.
The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.
Public Welfare Partnership: A Special Letter from the Jinan Red Cross
On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).
World’s First Achievement Highlights Brand Leadership
In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155515
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
